Here are the DEF 14A proxy statements from Avenue Therapeutics Inc (ATXI) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ATXI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATXI filings page.
Avenue Therapeutics, Inc. (ATXI) is asking stockholders to vote at its all-virtual 2025 Annual Meeting on December 30, 2025. Stockholders will elect six directors for one-year terms and ratify the appointment of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2025.
The proxy describes a six‑member board with a majority of independent directors and details audit and compensation committee structures, meeting attendance, and director qualifications. It explains that Fortress Biotech, Inc. beneficially owns more than 50% of the voting power and that Avenue relies on “controlled company” exemptions while still maintaining key independent oversight.
The filing outlines 2023–2024 executive and director compensation, including salaries, bonuses, stock options, and RSUs, as well as a new clawback policy and equity plan capacity of 4,575,701 shares available for future issuance. It also summarizes significant related‑party arrangements with Fortress, the 2022 acquisition and 2025 sale of Baergic, and the termination and transfer of the AJ201 program back to AnnJi, under which Avenue received $1.6 million in other revenue and agreed to a 48‑month non‑compete for competing products in key markets.